AU2020220895B9 - Use of topical BRaf inhibitor compositions for treatment of radiation dermatitis - Google Patents

Use of topical BRaf inhibitor compositions for treatment of radiation dermatitis Download PDF

Info

Publication number
AU2020220895B9
AU2020220895B9 AU2020220895A AU2020220895A AU2020220895B9 AU 2020220895 B9 AU2020220895 B9 AU 2020220895B9 AU 2020220895 A AU2020220895 A AU 2020220895A AU 2020220895 A AU2020220895 A AU 2020220895A AU 2020220895 B9 AU2020220895 B9 AU 2020220895B9
Authority
AU
Australia
Prior art keywords
grade
phenyl
rtog
composition
nci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020220895A
Other languages
English (en)
Other versions
AU2020220895A1 (en
AU2020220895B2 (en
Inventor
Noa LOWENTON-SPIER
Noa Shelach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lutris Pharma Ltd
Original Assignee
Lutris Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lutris Pharma Ltd filed Critical Lutris Pharma Ltd
Publication of AU2020220895A1 publication Critical patent/AU2020220895A1/en
Publication of AU2020220895B2 publication Critical patent/AU2020220895B2/en
Application granted granted Critical
Publication of AU2020220895B9 publication Critical patent/AU2020220895B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020220895A 2019-02-12 2020-02-11 Use of topical BRaf inhibitor compositions for treatment of radiation dermatitis Active AU2020220895B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804235P 2019-02-12 2019-02-12
US62/804,235 2019-02-12
PCT/IB2020/051073 WO2020165755A1 (en) 2019-02-12 2020-02-11 Use of topical braf inhibitor compositions for treatment of radiation dermatitis

Publications (3)

Publication Number Publication Date
AU2020220895A1 AU2020220895A1 (en) 2021-08-12
AU2020220895B2 AU2020220895B2 (en) 2022-11-17
AU2020220895B9 true AU2020220895B9 (en) 2023-02-02

Family

ID=72044789

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020220895A Active AU2020220895B9 (en) 2019-02-12 2020-02-11 Use of topical BRaf inhibitor compositions for treatment of radiation dermatitis

Country Status (17)

Country Link
US (1) US11439648B2 (https=)
EP (1) EP3923911B1 (https=)
JP (1) JP2022519675A (https=)
KR (1) KR102534457B1 (https=)
CN (1) CN113382717A (https=)
AU (1) AU2020220895B9 (https=)
BR (1) BR112021015137A2 (https=)
CA (1) CA3127175C (https=)
ES (1) ES2952251T3 (https=)
HR (1) HRP20231241T1 (https=)
HU (1) HUE063091T2 (https=)
IL (1) IL285560B2 (https=)
MX (1) MX2021009535A (https=)
PL (1) PL3923911T3 (https=)
RS (1) RS64618B1 (https=)
WO (1) WO2020165755A1 (https=)
ZA (1) ZA202106581B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116669739A (zh) * 2020-12-24 2023-08-29 鲁特里斯制药有限公司 用于治疗egfr下游效应物诱导的反应的局部braf抑制剂组合物
MX2024000227A (es) * 2021-07-02 2024-04-16 Lutris Pharma Ltd Uso de isoquinolina-1,5-diaminas para la curacion de heridas.
WO2023051685A1 (zh) * 2021-09-30 2023-04-06 北京大学 一种对红系前体细胞或成红细胞进行扩增的方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170100345A1 (en) * 2014-05-06 2017-04-13 The Regents Of The University Of California Wound healing using braf inhibitors
US20180369247A1 (en) * 2016-03-10 2018-12-27 Lutris Pharma Ltd. Use of braf inhibitors for treating cutaneous reactions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8557830B2 (en) 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
EP3147281A1 (en) * 2008-03-17 2017-03-29 Ambit Biosciences Corporation Quinazoline derivatives as raf kinase modulators and methods of use thereof
WO2011117381A1 (en) * 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
US20130226549A1 (en) 2012-02-27 2013-08-29 Yufeng J. Tseng Structure-based fragment hopping for lead optimization and improvement in synthetic accessibility
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
JP6912667B2 (ja) * 2017-07-29 2021-08-04 ルトリス ファーマ エル ティー ディー． 新規なｂｒａｆ阻害剤および皮膚反応を治療するためのその使用
WO2019032717A1 (en) * 2017-08-08 2019-02-14 Memorial Sloan Kettering Cancer Center USE OF BRAF INHIBITORS FOR TREATING SKIN REACTIONS CAUSED BY TREATMENT WITH MEK INHIBITOR

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170100345A1 (en) * 2014-05-06 2017-04-13 The Regents Of The University Of California Wound healing using braf inhibitors
US20180369247A1 (en) * 2016-03-10 2018-12-27 Lutris Pharma Ltd. Use of braf inhibitors for treating cutaneous reactions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANKER, CHRISTOPHER ET AL.:, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY* BIOLOGY* PHYSICS, vol. 95, no. 2, 9 November 2016, pages 632-646 *

Also Published As

Publication number Publication date
WO2020165755A1 (en) 2020-08-20
PL3923911T3 (pl) 2023-12-27
ES2952251T3 (es) 2023-10-30
US20210346389A1 (en) 2021-11-11
BR112021015137A2 (pt) 2021-09-28
HRP20231241T1 (hr) 2024-02-16
EP3923911A4 (en) 2022-11-09
HUE063091T2 (hu) 2024-01-28
CN113382717A (zh) 2021-09-10
EP3923911B1 (en) 2023-07-12
JP2022519675A (ja) 2022-03-24
ZA202106581B (en) 2022-09-28
IL285560B2 (en) 2024-04-01
CA3127175C (en) 2023-06-27
AU2020220895A1 (en) 2021-08-12
CA3127175A1 (en) 2020-08-20
RS64618B1 (sr) 2023-10-31
AU2020220895B2 (en) 2022-11-17
IL285560A (en) 2021-09-30
IL285560B1 (en) 2023-12-01
KR20210126665A (ko) 2021-10-20
EP3923911A1 (en) 2021-12-22
KR102534457B1 (ko) 2023-05-18
MX2021009535A (es) 2022-10-10
US11439648B2 (en) 2022-09-13
EP3923911C0 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
US5654312A (en) Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
US11439648B2 (en) Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis
CA2301009C (en) Skin care compositions and use
EP1147086A1 (en) Compositions for the treatment of skin diseases
WO2025090117A1 (en) Compositions and methods for treatment of wounds and inflammatory skin conditions
KR20230139402A (ko) 염증성 피부 증후군을 치료하는 약제학적인 용도의 화장품 조성물
HK1198632A1 (en) Compositions comprising cimetidine and n,o-carboxymethyl chitosan for the prevention and therapy of pathologies of the skin and the mucous membranes and in the odontostomatological field
RU2812708C2 (ru) Применение композиций на основе ингибитора braf для наружного применения для лечения лучевого дерматита
HUT74448A (en) Process for preparing pharmaceutical compns. contg. ibuprofen and flurbiprofen for use as anti-pruritic agents
EP4716539A1 (en) Pharmaceutical composition
JP5033381B2 (ja) 外用医薬組成物
AU2020282051B2 (en) Composition containing fluoxetine and vitamin D 3 or its derivatives and application thereof
JP5460766B2 (ja) 外用医薬組成物
US20250114362A1 (en) Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
US11052127B2 (en) HSP for use in treatment for imiquimod related side effects
JP2025091112A (ja) 皮膚外用剤組成物
JP2026506380A (ja) 皮膚の状態または疾患を処置する方法
PL211459B1 (pl) Zastosowanie czwartorzędowych soli pirydyniowych oraz preparat farmaceutyczny zawierający czwartorzędowe sole pirydyniowe
JP2000143518A (ja) 皮膚外用剤
CA2392544A1 (en) Natural therapeutic composition for the treatment of wounds and sores
JPS6056921A (ja) 皮膚外用剤

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)